|
注册号: Registration number: |
ChiCTR1900026133 |
|
最近更新日期: Date of Last Refreshed on: |
2020-07-12 23:18:58 |
|
注册时间: Date of Registration: |
2019-09-23 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
混合现实技术在复杂人工关节置换术中应用的安全性与有效性研究 |
|
Public title: |
Safety and efficacy of mixed reality in complex artificial joint replacement |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
混合现实技术在复杂人工关节置换术中应用的安全性与有效性研究 |
|
Scientific title: |
Safety and efficacy of mixed reality in complex artificial joint replacement |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
苏士龙 |
研究负责人: |
钟达 |
|
Applicant: |
Su Shilong |
Study leader: |
Zhong Da |
|
申请注册联系人电话: Applicant telephone: |
+86 15802667673 |
研究负责人电话:
Study leader's |
+86 13574890378 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1247622728@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
8148695@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国湖南长沙市湘雅路87号 |
研究负责人通讯地址: |
中国湖南长沙市湘雅路87号 |
|
Applicant address: |
87 Xiangya Road, Changsha, Hunan, China |
Study leader's address: |
87 Xiangya Road, Changsha, Hunan, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中南大学湘雅医院骨科 |
||
|
Applicant's institution: |
Department of Orthopedics, Xiangya Hospital, Central South University |
||
|
研究负责人所在单位: |
中南大学湘雅医院骨科 |
||
|
Affiliation of the Leader: |
Department of Orthopedics, Xiangya Hospital, Central South University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
202005134 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中南大学湘雅医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Xiangya Hospital Centre South University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-06-05 00:00:00 | ||
|
伦理委员会联系人: |
肖佩君 |
||
|
Contact Name of the ethic committee: |
Xiao Peijun |
||
|
伦理委员会联系地址: |
中国湖南长沙市湘雅路87号 |
||
|
Contact Address of the ethic committee: |
87 Xiangya Road, Changsha, Hunan, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 0731-84327919 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
xyyy11wyh@126.com |
|
研究实施负责(组长)单位: |
中南大学湘雅医院骨科 |
||||||||||||||||||||||
|
Primary sponsor: |
Department of Orthopedics, Xiangya Hospital, Central South University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国湖南长沙市湘雅路87号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
87 Xiangya Road, Changsha, Hunan, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
中南大学湘雅医院院内临床基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
Clinical research fund of Xiangya Hospital of Central South University |
||||||||||||||||||||||
|
研究疾病: |
复杂髋膝关节疾病 |
||||||||||||||||||||||
|
Target disease: |
Complex hip and knee diseases |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究以复杂髋关节和膝关节疾病患者为研究对象,通过混合现实技术辅助THA,TKA与传统方式THA,TKA的临床随机对照研究,评估混合现实技术相比于传统方式在围手术期及术后的临床疗效,安全性,实用性及可靠性。 |
||||||||||||||||||||||
|
Objectives of Study: |
In this study,patients diagnosed with complex hip and knee diseases were taken as the research object, and the clinical randomized controlled study of mixed reality assisted THA,TKA and traditional THA,TKA was conducted to evaluate the clinical efficacy, safety, practicability and reliability of mixed reality compared with traditional method in perioperative and postoperative period. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1. 拒绝参加; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Refuse to participate; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-01-01 00:00:00至 To 2023-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2020-01-01 00:00:00 至 To 2022-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由SPSS 软件产生随机序列,在产生随机序列后,将随机序列号按顺序进行编号,并决定哪些序列是试验组,哪些序列是对照组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Random sequences are generated by SPSS software. After random sequences are generated, random serial numbers are numbered in order and Determine which sequences are the test group and which are the control group. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
患者和观察人员对分配不知情 |
|
Blinding: |
Blind method for subjects and observers. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
采用Chictr.org.cn网络平台公开;ResMan, http://www.medresman.org.cn. |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Open the IPD on Chictr.org.cn;ResMan, http://www.medresman.org.cn. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据通过CRF表格记录 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The primary data were collected on Case-Report Form(CRF) |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |